Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

1(20%)

Results Posted

25%(1 trials)

Phase Distribution

Ph phase_2

60%

Ph phase_1

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

Phase 2Efficacy & side effects

3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(4)

Detailed Status

Completed4

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (40.0%)

Phase 23 (60.0%)

Trials by Status

recruiting120%

completed480%

Recent Activity

1 active trials

Showing 5 of 5

recruitingphase_1

Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors

NCT00002543

completedphase_2

Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00054808

Clinical Trials (5)

Showing 5 of 5 trials

NCT04294043Phase 1

IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)

Recruiting

NCT02354859Phase 2

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

Completed

NCT00002578Phase 2

Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

Completed

NCT00002543Phase 1

Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors

Completed

NCT00054808Phase 2

Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5